Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
US-2015087588-A1 · Mar 26, 2015 · US
Use of an adrenal hormone-modifying agent
US9434754B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9434754-B2 |
| Application number | US-201314079018-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 13, 2013 |
| Priority date | Jan 14, 2010 |
| Publication date | Sep 6, 2016 |
| Grant date | Sep 6, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a method of treating a disease or disorder characterized by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or —C(O)N(R a )(R b ) wherein R a and R b are independently —(C 1 -C 4 ) alkyl, or —(C 1 -C 4 ) alkyl-(C 5 -C 7 ) aryl, wherein each of R a and R b is optionally substituted by —(C 1 -C 4 ) alkoxy; R 1 , R 2 , and R 3 , are independently hydrogen, halogen, cyano or —(C 6 -C 10 ) aryl, wherein said —(C 6 -C 10 ) aryl is optionally substituted by halogen, with the proviso that no more than one of R 1 , R 2 , and R 3 is hydrogen; and R 4 and R 5 are hydrogen; or a pharmaceutically acceptable salt thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound which is 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile dihydrogen phosphate; or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
- A61K31/4188Primary
condensed with other heterocyclic ring systems, e.g. biotin, sorbinil · CPC title
- C07F9/6506Primary
having the nitrogen atoms in positions 1 and 3 · CPC title
having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title
- C07D487/04Primary
Ortho-condensed systems · CPC title
Drugs for disorders of the endocrine system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9434754B2 cover?
- The present invention relates to a method of treating a disease or disorder characterized by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or —C(O)N(R a )(R b ) wherein R a and R b are independent…
- Who is the assignee on this patent?
- Hu Qi-Ying, Ksander Gary Michael, Meredith Erik, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4188. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).